- Home
- OSTX vs QNCX Comparison
OSTX vs QNCX Comparison
Compare OSTX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- QNCX
- Stock Information
- Founded
- OSTX 2018
- QNCX 2012
- Country
- OSTX United States
- QNCX United States
- Employees
- OSTX N/A
- QNCX N/A
- Industry
- OSTX
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OSTX
- QNCX Health Care
- Exchange
- OSTX NYSE
- QNCX Nasdaq
- Market Cap
- OSTX 43.0M
- QNCX 47.7M
- IPO Year
- OSTX 2024
- QNCX 2019
- Fundamental
- Price
- OSTX $1.81
- QNCX $1.31
- Analyst Decision
- OSTX Strong Buy
- QNCX Strong Buy
- Analyst Count
- OSTX 3
- QNCX 5
- Target Price
- OSTX $18.00
- QNCX $8.00
- AVG Volume (30 Days)
- OSTX 302.3K
- QNCX 304.4K
- Earning Date
- OSTX 08-14-2025
- QNCX 08-12-2025
- Dividend Yield
- OSTX N/A
- QNCX N/A
- EPS Growth
- OSTX N/A
- QNCX N/A
- EPS
- OSTX N/A
- QNCX N/A
- Revenue
- OSTX N/A
- QNCX N/A
- Revenue This Year
- OSTX N/A
- QNCX N/A
- Revenue Next Year
- OSTX N/A
- QNCX N/A
- P/E Ratio
- OSTX N/A
- QNCX N/A
- Revenue Growth
- OSTX N/A
- QNCX N/A
- 52 Week Low
- OSTX $1.12
- QNCX $0.51
- 52 Week High
- OSTX $7.00
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- QNCX 64.64
- Support Level
- OSTX N/A
- QNCX $1.29
- Resistance Level
- OSTX N/A
- QNCX $1.45
- Average True Range (ATR)
- OSTX 0.00
- QNCX 0.09
- MACD
- OSTX 0.00
- QNCX 0.03
- Stochastic Oscillator
- OSTX 0.00
- QNCX 76.74
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.